📣 VC round data is live. Check it out!

Darya-Varia Laboratoria Valuation Multiples

Discover revenue and EBITDA valuation multiples for Darya-Varia Laboratoria and similar public comparables like Aldeyra Therapeutics, Rani Therapeutics, Vistin Pharma, Biomea Fusion and more.

Darya-Varia Laboratoria Overview

About Darya-Varia Laboratoria

PT Darya-Varia Laboratoria Tbk (Darya-Varia) is operating in the pharmaceutical industry. It is engaged in the manufacture and trade of pharmaceutical products, human, traditional medicines, pharmaceutical materials, raw materials for traditional medicines, inorganic base chemicals, organic base chemicals, equipment for surgery, medical and dental care, medical and dental equipment, orthopedic equipment, prosthetic, eyeglasses, laboratory and health equipment from glass, cosmetics; wholesaler of pharmaceutical, traditional medicine, chemical base materials, laboratory equipment, cosmetic; wholesale trade in pharmaceuticals; laboratory testing services, health support service activities, research and development, periodic inspection services, and many more activities.


Founded

1976

HQ

Indonesia

Employees

1.7K

Financials (FY)

Revenue: $125M
EBITDA: $15M

EV

$80M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Darya-Varia Laboratoria Financials

Darya-Varia Laboratoria reported last fiscal year revenue of $125M and EBITDA of $15M.

In the same fiscal year, Darya-Varia Laboratoria generated $68M in gross profit, $15M in EBITDA, and $9M in net income.


Darya-Varia Laboratoria P&L

In the most recent fiscal year, Darya-Varia Laboratoria reported revenue of $125M and EBITDA of $15M.

Darya-Varia Laboratoria is profitable as of last fiscal year, with gross margin of 54%, EBITDA margin of 12%, and net margin of 7%.

See analyst estimates for Darya-Varia Laboratoria
Last FY202320242025202620272028
Revenue$125M$106M$117M$125M
Gross Profit$68M$55M$62M$68M
Gross Margin54%52%53%54%
EBITDA$15M$13M$14M$15M
EBITDA Margin12%12%12%12%
EBIT Margin9%9%9%9%
Net Profit$9M$8M$9M$9M
Net Margin7%8%7%7%

Financial data powered by Morningstar, Inc.

Darya-Varia Laboratoria Stock Performance

Darya-Varia Laboratoria has current market cap of $100M, and enterprise value of $80M.

Market Cap Evolution


Darya-Varia Laboratoria's stock price is $0.09.

Darya-Varia Laboratoria share price decreased by 6.2% in the last year.

Darya-Varia Laboratoria has an EPS (earnings per share) of $0.01.

See more trading valuation data for Darya-Varia Laboratoria
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$80M$100M-0.0%-0.0%-5.0%-6.2%$0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Darya-Varia Laboratoria Valuation Multiples

Darya-Varia Laboratoria trades at 0.6x EV/Revenue multiple, and 5.5x EV/EBITDA.

See NTM and 2027E valuation multiples for Darya-Varia Laboratoria

Darya-Varia Laboratoria Financial Valuation Multiples

As of June 2, 2026, Darya-Varia Laboratoria has market cap of $100M and EV of $80M.

Darya-Varia Laboratoria has a P/E ratio of 10.8x.

Last FY202320242025202620272028
EV/Revenue0.6x0.8x0.7x0.6x
EV/EBITDA5.5x6.3x5.8x5.5x
EV/EBIT7.0x8.1x7.3x7.0x
EV/Gross Profit1.2x1.5x1.3x1.2x
P/E10.8x12.1x11.4x10.8x
EV/FCF15.3x127.2x6.3x15.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Darya-Varia Laboratoria Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Darya-Varia Laboratoria Margins & Growth Rates

In the most recent fiscal year, Darya-Varia Laboratoria reported gross margin of 54%, EBITDA margin of 12%, and net margin of 7%.

See estimated margins and future growth rates for Darya-Varia Laboratoria

Darya-Varia Laboratoria Margins

Last FY20242025202720282029
Gross Margin54%53%54%
EBITDA Margin12%12%12%
EBIT Margin9%9%9%
Net Margin7%7%7%
FCF Margin4%11%4%

Darya-Varia Laboratoria Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth10%7%
Gross Profit Growth12%11%
EBITDA Growth8%6%
EBIT Growth11%5%
Net Profit Growth7%5%
FCF Growth1933%(59%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Darya-Varia Laboratoria Operational KPIs

Darya-Varia Laboratoria's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.

Access forward-looking KPIs for Darya-Varia Laboratoria
Last FY202320242025202620272028
Revenue per Employee$0.1M---
Opex per Employee$0.0M---
S&M Expenses to Revenue22%19%20%22%
G&A Expenses to Revenue5%5%5%5%
Opex to Revenue45%42%43%45%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Darya-Varia Laboratoria Competitors

Darya-Varia Laboratoria competitors include Aldeyra Therapeutics, Rani Therapeutics, Vistin Pharma, Biomea Fusion, Cardiff Oncology, Ryvu Therapeutics, PepGen, Verrica Pharmaceuticals, Rallybio and Cue Biopharma.

Most Darya-Varia Laboratoria public comparables operate across Biopharmaceuticals, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Aldeyra Therapeutics-5.5x(1.6x)-
Rani Therapeutics37.1x22.6x(1.6x)-
Vistin Pharma2.0x-7.6x-
Biomea Fusion--(0.7x)(0.7x)
Cardiff Oncology92.9x123.9x(1.1x)-
Ryvu Therapeutics4.3x3.2x(4.5x)(7.2x)
PepGen--0.2x-
Verrica Pharmaceuticals2.3x2.6x(8.8x)-

This data is available for Pro users. Sign up to see all Darya-Varia Laboratoria competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Darya-Varia Laboratoria

Who are competitors of Darya-Varia Laboratoria?Darya-Varia Laboratoria main competitors include Aldeyra Therapeutics, Rani Therapeutics, Vistin Pharma, Biomea Fusion, Cardiff Oncology, Ryvu Therapeutics, PepGen, Verrica Pharmaceuticals, Rallybio, Cue Biopharma.

See public comps similar to Darya-Varia Laboratoria

Lists including Darya-Varia Laboratoria

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial